233 South Tenth Street
Bluemle Life Sciences Building, Room 531
Philadelphia, PA 19107-5541
(215) 503-4634
(215) 503-5393 fax
Bluemle Life Sciences Building, Room 531
Philadelphia, PA 19107-5541
(215) 503-4634
(215) 503-5393 fax
Most Recent Peer-reviewed Publications
- Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2
- Rhabdoviruses as vectors for vaccines and therapeutics
- Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups
- Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor
- Publisher Correction: Rabies-based vaccine induces potent immune responses against Nipah virus (npj Vaccines, (2019), 4, 1, (15), 10.1038/s41541-019-0109-5)
- Rabies-based vaccine induces potent immune responses against Nipah virus
- Inactivated Rabies Virus-Based Ebola Vaccine Preserved by Vaporization Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge
- Persistence of Lassa Virus Associated with Severe Systemic Arteritis in Convalescing Guinea pigs (Cavia porcellus)
- A new recombinant rabies virus expressing a green fluorescent protein: A novel and fast approach to quantify virus neutralizing antibodies
- Avoiding preventable deaths: The scourge of counterfeit rabies vaccines
- Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses
- Non-neutralizing antibodies elicited by recombinant Lassa–Rabies vaccine are critical for protection against Lassa fever
- New developments in rabies vaccination
- Retrograde axonal transport of rabies virus is unaffected by interferon treatment but blocked by emetine locally in axons
- The spread and evolution of rabies virus: Conquering new frontiers
- Ebola Virus Localization in the Macaque Reproductive Tract during Acute Ebola Virus Disease
- Ifit2 is a restriction factor in rabies virus pathogenicity
- Progress in Ebola Virus Vaccine Development
- Inactivated recombinant rabies viruses displaying canine distemper virus glycoproteins induce protective immunity against both pathogens
- The final (Oral Ebola) vaccine trial on captive chimpanzees?
- Toward an Effective Ebola Virus Vaccine
- One-Health: A safe, efficient, dual-use vaccine for humans and animals against middle east respiratory syndrome coronavirus and rabies virus
- Keeping it in check: Chronic viral infection and antiviral immunity in the brain
- An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted with Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models
- Rabies Virus CVS-N2cδG Strain Enhances Retrograde Synaptic Transfer and Neuronal Viability